We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo (MASI) Launches Root Platform with Kite Trademark
Read MoreHide Full Article
Irvine, CA-based Masimo Corporation (MASI - Free Report) announced full market release of the Root monitoring platform with a Kite trademark (a supplementary display system). Root is a patient monitoring and connectivity platform. It offers the company’s flagship rainbow and Masimo SET measurements with other parameters in an integrated, ‘clinician-centric’ platform to enable clinicians to track blood pressure, temperature, oxygen saturation and pulse rate with a single monitor unit.
Coming to the latest progress, Root is now available in the markets with the Kite display system. Notably, Kite connects to Root via a wired or wireless system and showcases relevant patient data on a smart TV.
The Kite trademark exclusively highlights the ‘versatility and flexibility’ of the Root platform. With the latest development, Masimo aims to focus on relevant patient data by minimizing the bottlenecks that clinicians face during their clinical analysis, per management.
Meanwhile, the company has been gaining prominence in the niche markets with its wide portfolio, including a few highly exclusive sensors. In this regard, Masimo announced the availability of the RD SedLine EEG sensor last month. The newly released sensor can be used with the company’s flagship SedLine Brain Function Monitoring technology. Earlier this year, Masimo got a CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.
Favorable Share Price & Estimate Revision Trend
Masimo has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 38.2%, higher than the Zacks categorized Medical instruments sub-industry’s addition of almost 5.2%.
Moreover, the current level compares favorably with the S&P 500’s return of 5.9% over the same time frame. This, together with a long-term expected earnings growth rate of 15%, instills confidence in investors.
Furthermore, the estimate revision for the stock has been quite favorable. The year has seen five estimates move north over the last two months, compared with no movement in the opposite direction. As a result, the full year estimates jumped 6.4% to $2.32 over the same time frame.
Driven by bullish analyst sentiments, Masimo Stock sports a Zacks Rank #2 (Buy), signifying probabilities of outperformance in the near term.
Our Take
We believe that the Kite trademark has upgraded the Root platform to a ‘clinician-friendly’ monitoring system. This is because multiple data outputs from different methods of patient monitoring can now be displayed on a large, centrally-located screen, in the clinicians’ preferred configuration.
Masimo has got strong fundamentals and has a significant share of business overseas as well. The recent launch of advanced monitoring technologies in the Indian market (introduction of its proprietary Rad-97 Pulse-CO Oximeter and Next Generation SedLine Brain Function Monitoring) is a prudent move in fortifying the company’s market position internationally.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 64.2%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a stellar one-year return of roughly 21.3%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last 3–5 years of actual earnings) of almost 22%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Masimo (MASI) Launches Root Platform with Kite Trademark
Irvine, CA-based Masimo Corporation (MASI - Free Report) announced full market release of the Root monitoring platform with a Kite trademark (a supplementary display system). Root is a patient monitoring and connectivity platform. It offers the company’s flagship rainbow and Masimo SET measurements with other parameters in an integrated, ‘clinician-centric’ platform to enable clinicians to track blood pressure, temperature, oxygen saturation and pulse rate with a single monitor unit.
Coming to the latest progress, Root is now available in the markets with the Kite display system. Notably, Kite connects to Root via a wired or wireless system and showcases relevant patient data on a smart TV.
Masimo Corporation Price
Masimo Corporation Price | Masimo Corporation Quote
The Kite trademark exclusively highlights the ‘versatility and flexibility’ of the Root platform. With the latest development, Masimo aims to focus on relevant patient data by minimizing the bottlenecks that clinicians face during their clinical analysis, per management.
Meanwhile, the company has been gaining prominence in the niche markets with its wide portfolio, including a few highly exclusive sensors. In this regard, Masimo announced the availability of the RD SedLine EEG sensor last month. The newly released sensor can be used with the company’s flagship SedLine Brain Function Monitoring technology. Earlier this year, Masimo got a CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.
Favorable Share Price & Estimate Revision Trend
Masimo has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 38.2%, higher than the Zacks categorized Medical instruments sub-industry’s addition of almost 5.2%.
Moreover, the current level compares favorably with the S&P 500’s return of 5.9% over the same time frame. This, together with a long-term expected earnings growth rate of 15%, instills confidence in investors.
Furthermore, the estimate revision for the stock has been quite favorable. The year has seen five estimates move north over the last two months, compared with no movement in the opposite direction. As a result, the full year estimates jumped 6.4% to $2.32 over the same time frame.
Driven by bullish analyst sentiments, Masimo Stock sports a Zacks Rank #2 (Buy), signifying probabilities of outperformance in the near term.
Our Take
We believe that the Kite trademark has upgraded the Root platform to a ‘clinician-friendly’ monitoring system. This is because multiple data outputs from different methods of patient monitoring can now be displayed on a large, centrally-located screen, in the clinicians’ preferred configuration.
Masimo has got strong fundamentals and has a significant share of business overseas as well. The recent launch of advanced monitoring technologies in the Indian market (introduction of its proprietary Rad-97 Pulse-CO Oximeter and Next Generation SedLine Brain Function Monitoring) is a prudent move in fortifying the company’s market position internationally.
Other Key Picks
Other top-ranked stocks stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 64.2%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a stellar one-year return of roughly 21.3%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last 3–5 years of actual earnings) of almost 22%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>